Display options
Cite
Czupryniak L, Danne T, Szymańska-Garbacz E, et al. Sodium-glucose co-transporter-2 inhibitors for type 1 diabetes: Not any more?. Diabetes Obes Metab. 2021;doi: 10.1111/dom.14631.
Czupryniak, L., Danne, T., Szymańska-Garbacz, E., Zozulińska-Ziółkiewicz, D., Gumprecht, J., & Klupa, T. (2021). Sodium-glucose co-transporter-2 inhibitors for type 1 diabetes: Not any more?. Diabetes, obesity & metabolism, . https://doi.org/10.1111/dom.14631
Czupryniak, Leszek, et al. "Sodium-glucose co-transporter-2 inhibitors for type 1 diabetes: Not any more?." Diabetes, obesity & metabolism vol. (2021). doi: https://doi.org/10.1111/dom.14631
Czupryniak L, Danne T, Szymańska-Garbacz E, Zozulińska-Ziółkiewicz D, Gumprecht J, Klupa T. Sodium-glucose co-transporter-2 inhibitors for type 1 diabetes: Not any more?. Diabetes Obes Metab. 2021 Dec 21; doi: 10.1111/dom.14631. Epub 2021 Dec 21. PMID: 34931428.
Copy Download .nbib Format: NLM
Share it on

Diabetes Obes Metab. 2021 Dec 21; doi: 10.1111/dom.14631. Epub 2021 Dec 21.

Sodium-glucose co-transporter-2 inhibitors for type 1 diabetes: Not any more?.

Diabetes, obesity & metabolism

Leszek Czupryniak, Thomas Danne, Elektra Szymańska-Garbacz, Dorota Zozulińska-Ziółkiewicz, Janusz Gumprecht, Tomasz Klupa

Affiliations

  1. Department of Diabetology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
  2. Diabetes Center AUF DER BULT, Hannover Medical School, Hannover, Germany.
  3. Department of Internal Medicine and Nephrodiabetology, Medical University of Lodz, Lodz, Poland.
  4. Department of Internal Medicine and Diabetology, Poznan University of Medical Sciences, Poznan, Poland.
  5. Department of Internal Medicine, Diabetology and Nephrology, Medical University of Silesia, Zabrze, Poland.
  6. Unit on Advanced Technologies in Diabetes, Department of Metabolic Diseases, Jagiellonian University Medical College, Krakow, Poland.

PMID: 34931428 DOI: 10.1111/dom.14631

[No abstract available.]

References

  1. https://www.astrazeneca.com/media-centre/press-releases/2019/forxiga-approved-in-europe-for-type-1-diabetes22032019.html#. Accessed October 30, 2021 - PubMed
  2. Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(11):864-876. - PubMed
  3. Mathieu C, Rudofsky G, Phillip M, et al. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial. Diabetes Obes Metab. 2020;22(9):1516-1526. - PubMed
  4. Taylor SI, Blau JE, Rother KI, Beitelshees AL. SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks. Lancet Diabetes Endocrinol. 2019;7(12):949-958. - PubMed
  5. Morales C, Bellido V, Tejera C, et al. DAPA-RWE: a retrospective multicenter study comparing dapagliflozin and sitagliptin in patients with Type 2 diabetes treated under routine clinical practice in Spain. J Comp Eff Res. 2021;10(10):815-821. - PubMed
  6. Goldenberg RM, Gilbert JD, Hramiak IM, Woo VC, Zinman B. Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol. Diabetes Obes Metab. 2019;21(10):2192-2202. - PubMed
  7. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. - PubMed
  8. Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2021;64(12):2609-2652. - PubMed
  9. https://www.ema.europa.eu/en/medicines/dhpc/forxiga-dapagliflozin-5mg-should-no-longer-be-used-treatment-type-1-diabetes-mellitus. Accessed October 30, 2021. - PubMed
  10. Hughes MS, Bailey R, Calhoun P, Shah VN, Lyons SK, DeSalvo DJ. Off-label use of sodium glucose co-transporter inhibitors among adults in type 1 diabetes exchange registry. Diabetes Obes Metab. 2022;24(1):171-173. - PubMed
  11. Danne T, Garg S, Peters AL, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care. 2019;42(6):1147-1154. - PubMed
  12. Seufert J, Lanzinger S, Danne T, et al. Real-world data of 12-month adjunct sodium-glucose co-transporter-2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV Registry: improved HbA1c without diabetic ketoacidosis [published online ahead of print December 12, 2021]. Diabetes Obes Metab. doi:10.1111/dom.14620 - PubMed
  13. https://www.astrazeneca.com/our-company/our-commitment-to-patients.html. Accessed October 30, 2021. - PubMed

Publication Types